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Summary
 
Transplantation of genetically marked donor cells in mice have unambiguously identified indi-
vidual clones with full differentiative potential in all lymphoid and myeloid pathways. Such evi-
dence has been lacking in humans because of limitations inherent to clonal stem cell assays. In
this work, we used single cell cultures to show that human cord blood (CB) contains totipotent
CD34
 
1
 
 cells capable of T, B, natural killer, and granulocytic cell differentiation. Single CD34
 
1
 
CD19
 
2
 
Thy1
 
1
 
 (or CD38
 
2
 
) cells from fresh CB were first induced to proliferate and their prog-
eny separately studied in mouse fetal thymic organotypic cultures (FTOCs) and cocultures on
murine stromal feeder layers. 10% of the clones individually analyzed produced CD19
 
1
 
, CD56
 
1
 
,
and CD15
 
1
 
 cells in stromal cocultures and CD4
 
1
 
CD8
 
1
 
 T cells in FTOCs, identifying totipotent
progenitor cells. Furthermore, we showed that totipotent clones with similar lymphomyeloid
potential are detected in the bone marrow of nonobese diabetic severe combined immunodefi-
cient (NOD-SCID) mice transplanted 4 mo earlier with human CB CD34
 
1
 
 cells. These results
provide the first direct demonstration that human CB contains totipotent lymphomyeloid pro-
genitors and transplantable CD34
 
1
 
 cells with the ability to reconstitute, in the marrow of re-
cipient mice, the hierarchy of hematopoietic compartments, including a compartment of func-
tional totipotent cells. These experimental approaches can now be exploited to analyze
mechanisms controlling the decisions of such primitive human progenitors and to design con-
ditions for their ampification that can be helpful for therapeutic purposes.
Key words: stem cells • fetal thymic organotypic culture • nonobese diabetic-severe combined 
immunodeﬁcient • lymphopoiesis • hematopoiesis
 
S
 
yngeneic transplantation approaches using genetically
marked stem cells (1, 2) or limited numbers of them (3,
4) have led to the identification of murine progenitor cells
with multiple differentiative potentials. These strategies
have been exploited to analyze the contribution of stem
cell populations to short- and long-term hematopoietic re-
constitution (5) and define conditions for their amplifica-
tion (or self-renewal) (6). Both issues have an obvious clin-
ical relevance, but experimental strategies used in mice
cannot be easily applied to human cells (7). Although en-
graftment is the rule after injection of human cells into im-
munodeficient mice (8–12), there is no definite proof as yet
that the entity defined as nonobese diabetic (NOD)
 
1
 
-
SCID–repopulating cells (13, 14) is a reliable indicator of
long-term reconstituting human stem cell function. One
important limitation both in vitro and in vivo has been the
difficulty in obtaining efficient lymphoid differentiation
from primitive human progenitors. Thus, in NOD-SCID
recipients, lymphoid differentiation is restricted to the de-
velopment of the B cell lineage (8, 9, 12), and mature T or
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CB, cord blood;
 
 
 
DP, double positive;
FTOCs, fetal thymic organotypic cultures; Gr/M, granulomonocytic;
MGDF, megakaryocyte growth and differentiation factor;
 
 
 
NOD, nonobese
diabetic; PEG, pegylated;
 
 
 
rhu, recombinant human; SCF, stem cell factor.  
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NK cells are produced very rarely or not at all (9). It is
presently unknown whether this defect is accounted for by
the fact that regulatory controls do not operate in these
chimeras or because engrafted human CD34
 
1
 
 cells have an
impaired T and NK potential. In the case of T cells, differ-
entiation can be rescued by the coimplantation of human
thymic tissue (15), and data in favor of a migration defect
have recently been provided (16). In contrast to the chi-
meric in vivo situation, high numbers of functional, mature
NK and dendritic cells can be obtained in vitro from vari-
ous cell sources if appropriate cytokines are provided (17,
18). Human B cell differentiation requires stromal feeders,
and, unexpectedly, decisive progress in the production of
CD19
 
1
 
 B cells from human primitive progenitors has re-
sulted from the use of murine (as opposed to human) stro-
mal cells (19, 20). The T cell potential of primitive CD34
 
1
 
human cells can also be successfully identified in fetal thy-
mic organotypic cultures (FTOCs) using embryonic thy-
mic lobes from both normal (21) or immunodeficient mice
(including NOD-SCID mice) (22–24). However, even
though FTOC conditions can be manipulated to obtain B,
NK, and myeloid cells in addition to T cells, at least in
mice (25, 26), cocultures of human CD34
 
1
 
 populations on
stromal feeders, even if they are derived from the thymus,
do not reproducibly allow T cell differentiation (27), and
the identification of individual cells with all possible lym-
phoid and myeloid potentials still requires the use of sepa-
rate assays (28).
In this study, we show for the first time that in vitro
conditions exist that allow investigators to reproducibly as-
sess all lymphoid (T, B, NK) and some myeloid potentials
from single CD34
 
1
 
CD19
 
2
 
Thy1
 
1
 
 human cord blood (CB)
cells. The strategy first requires induction of cell prolifera-
tion with cytokines to separately assess T cell potential in
FTOCs and NK cell, B cell, and myeloid potentials in a
unique coculture assay using MS5 murine stromal feeder
layers. We also detected totipotent cells in the marrow of
NOD-SCID recipient mice 4 mo after their transplantation
with CD34
 
1
 
 CB cells. Taken together, our data demon-
strate that human CB contains totipotent cells and in vivo–
transplantable cells with similar lymphomyeloid differentia-
tive potentials. This strongly suggests that cells exist in CB
that have some characteristics of true stem cells.
 
Materials and Methods
 
Collection and Fractionation of Cells.
 
CB samples were col-
lected with the informed consent of the mothers involved in our
study. Low density CB mononuclear cells were first subjected to
a standard CD34 immunomagnetic bead separation using the
miniMACS
 
®
 
 system (Miltenyi Biotec). Bead-separated CD34
 
1
 
cells (purity 
 
.
 
75%) were either injected into NOD-SCID mice
(10
 
5
 
 cells/mouse) or further fractionated in CD34
 
1
 
CD19
 
2
 
CD38
 
2
 
 or CD34
 
1
 
CD19
 
2
 
Thy1
 
1
 
 fractions by cell sorting using a
FACS Vantage™ equipped with an argon ion laser (Innova 70-
4-coherent radiation) tuned to 488 nm and operating at 500 Mw.
A morphological gate including all of the CD34
 
1
 
 cells was first
defined on two-parameter histograms, side scatter versus forward
scatter. Positivity or negativity for CD19, Thy1, and CD38
among the CD34
 
1
 
 cells was determined using cells labeled with
CD34-PE-Cy5 (Immunotech) and an irrelevant IgG1 mAb. The
Thy1
 
1
 
 and CD38
 
2
 
 subsets of CD34
 
1
 
 cells were obtained in two
steps. CD34
 
1
 
CD19
 
2
 
 cells were sorted and relabeled with CD34-
PE-Cy5 (Immunotech) and either CD38-PE (Becton Dickin-
son), or Thy1 (CD90)-PE (PharMingen). Limits of the sorting
gates for Thy1
 
1
 
 and CD38
 
2
 
 cells were set as illustrated (see Fig.
1). Single cell cultures were initiated by directly sorting cells into
96-well tissue culture plates precoated with MS5 murine stromal
cells using an automatic cloning design unit (Becton Dickinson).
The standardized distribution of one cell per well was controlled
by examining over 4,000 wells individually in parallel experi-
ments initiated with human cells.
For in vivo experiments, 10
 
5
 
 CB CD34
 
1
 
 cells were intrave-
nously injected into irradiated (3–3.5 Gy; cobalt-60 Eldorado S
irradiator; AECL Medical) NOD-LtSz-
 
scid/scid
 
 (hereafter called
NOD-SCID) mice anesthesized briefly with ether. 10–16 wk
later, marrow cells were flushed from the femurs and tibias of re-
cipient mice as previously described (12), and human CD34
 
1
 
cells were isolated and fractionated into CD34
 
1
 
CD19
 
2
 
, CD34
 
1
 
CD19
 
2
 
Thy1
 
1
 
, or CD34
 
1
 
CD19
 
2
 
CD38
 
2
 
 as indicated above (see
Fig. 1).
 
Assessment of Human T Cell Potential in FTOC.
 
Isolation of
murine embryonic thymic lobes, incubation with human cells af-
ter the hanging drop procedure, and organotypic cultures were
performed following standard procedures initially described to
analyze mouse T lymphoid differentiation and adapted to the
identification of human T cell potential (22, 29). Our slight mod-
ifications of the technique included the use of NOD-SCID em-
bryonic (day 14) thymic lobes and the addition of recombinant
human (rhu) IL-2 (5 ng/ml; Diaclone), 20 ng/ml rhu-IL-7 (Dia-
clone), and 50 ng/ml rhu-stem cell factor (SCF; provided by
Amgen) during the hanging drop procedure. Thymic lobes were
incubated onto floating filters (Isopore membrane, 25-mm diam-
eter, 8-
 
m
 
m pore size; Millipore SA) at 37
 
8
 
C and 5% CO
 
2 
 
in me-
dium without cytokines. Cells recovered from the thymic lobes
after 28–35 d were labeled with anti–human CD4-PE and CD8-
FITC (Becton Dickinson), TCR-
 
a/b
 
-PE, and CD3-FITC (Im-
munotech). Lack of reactivity of the mouse anti–human mAbs
with NOD-SCID murine cells was verified in pilot experiments
(12, 24).
 
Simultaneous Assessment of B, NK, and Granulomonocytic (Gr/M)
Differentiation.
 
The different cell fractions were incubated in 24- or
96-well plates precoated with confluent murine marrow–derived
MS5 cells (30) in RPMI supplemented with 10% human serum, 5%
FCS, and the following six rhu cytokines: rhu-SCF (50 ng/ml;
Amgen), rhu-Flt3-ligand (50 ng/ml; Diaclone), pegylated (PEG)-
rhu-megakaryocyte growth and differentiation factor (MGDF) (50
ng/ml; Amgen), rhu-IL-2 (5 ng/ml; Diaclone), rhu-IL-15 (10 ng/
ml; Diaclone), and rhu-IL-7 (20 ng/ml; Diaclone). Wells with sig-
nificant cell proliferation (usually 
 
.
 
500 cells after 3–6 wk) were se-
lected, and cells were collected and their phenotype assessed by flow
cytometry after labeling with the following mAbs: CD19-PE (Bec-
ton Dickinson), CD15-FITC (Dako Corp.), and CD56-PE-Cy5,
CD34-PE-Cy5, CD1a-PE, and HLA-DR-FITC (all from Immu-
notech). In some experiments, the intracellular expression of my-
eloperoxidase (MPO; Caltag Labs.) was determined using a cell per-
meabilization kit (Harlan, Sera-Lab Ltd.). Analysis was performed
on a FACScan™ (Becton Dickinson) using CellQuest software.
 
Analysis of the Lymphoid and Gr/M Potentials of Single Progenitors.
 
Individual CD34
 
1
 
CD19
 
2
 
, CD34
 
1
 
CD19
 
2
 
Thy1
 
1
 
, or CD34
 
1
 
CD19
 
2
 
CD38
 
2
 
 cells from either fresh CB or the marrow of chi- 
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meric NOD-SCID mice 4 mo posttransplant were induced to
proliferate in 96-well plates precoated with MS5 cells in the pres-
ence of the six growth factors listed above. Wells were carefully
monitored for 7–21 d, and clones containing 
 
$
 
1,000 cells were
divided: for each clone, half of the cells were cultured on new
MS5 feeders as described above and the other half were incubated
in NOD-SCID FTOC together with 5,000 irradiated (15 Gy)
CD34
 
1
 
CD38
 
1
 
 CB cells, as accessory cells have been shown to
help engraftment in FTOC seeded with small numbers of cells
(24). At the end of the FTOC, cells collected from each lobe were
analyzed individually for the presence of CD4
 
bright 
 
and/or CD4
 
1
 
CD8
 
1
 
 human cells. In three control experiments, 25 NOD-SCID
fetal thymic lobes were reconstituted with 10,000 irradiated, fresh
CD34
 
1
 
CD38
 
1
 
 cells/lobe, but none of them yielded human T
cells. In contrast, all lobes incubated with unirradiated CD34
 
1
 
CD38
 
1
 
 cells produced CD4
 
bright
 
 and CD4
 
1
 
CD8
 
1
 
 T cells (not
shown).
 
Results
 
Selection of Human Cells from Fresh CB and from the Marrow
of NOD-SCID Mice Transplanted with CB CD34
 
1
 
 Cells.
 
Because primitive lymphomyeloid cells most likely repre-
sent only a minor fraction of human CD34
 
1
 
 cells collected
from both fresh CB and NOD-SCID marrow, we per-
formed an enrichment step. We first removed CD34
 
1
 
CD19
 
1
 
 committed pre-B cells, which represented 13 
 
6
 
8% (
 
n
 
 5 
 
6) of fresh CB cells (Fig. 1 A) but 83 
 
6
 
 6% (
 
n
 
 5
 
11) of NOD-SCID–derived CD34
 
1
 
 cells (Fig. 1 C) (12).
CD34
 
1
 
CD19
 
2
 
 cells were further fractionated into Thy1
 
1
 
or CD38
 
2
 
 cells, as both cell types exhibit primitive func-
tions. Thy1
 
1
 
 cells represented 10 
 
6
 
 4% (
 
n
 
 5 
 
5) of fresh
CD34
 
1
 
CD19
 
2
 
 CB cells (Fig. 1 B), whereas Thy1
 
1
 
 (Fig.
1 D) and CD38
 
2
 
 (Fig. 1 E) cells accounted only for 2.5 
 
6
 
1.8% and 2.3 
 
6
 
 0.6% of CD34
 
1
 
CD19
 
2
 
 cells from NOD-
SCID mice (
 
n
 
 5 
 
5), respectively.
 
B, NK, and Gr/M Cell Differentiation Potentials of CD34
 
1
 
Subsets from Fresh CB and the Marrow of NOD-SCID Mice
Transplanted with Human CD34
 
1
 
 CB Cells.
 
We have pre-
viously shown that murine MS5 stromal cells support my-
eloid (30) and B cell differentiation (20) from CD34
 
1
 
 CB
cells when studied in separate assays but also from single
bipotent B/myeloid progenitors in a switch system (20).
 
Because MS5 cells also promote the production of NK cells
from CD34
 
1
 
 cells in the presence of human IL-15 (31), we
reasoned that slight modifications of these culture conditions
should allow the simultaneous development of all three lin-
eages (B, NK, and Gr/M). To this end, we supplemented
the medium with rhu-SCF, IL-2, IL-15 (three-cytokine
condition), and, in later experiments, PEG-rhu-MGDF,
Flt3-ligand, and IL-7 were also added (six-cytokine condi-
tion). PEG-rhuMGDF and Flt3-ligand were chosen to trig-
ger active proliferation of immature progenitors that may not
respond to lineage-specific cytokines (32), and IL-7 was cho-
sen to minimize the loss of B and/or T cell potential (33).
Thus, CD34
 
1CD192 and CD341CD192Thy11 fresh
CB cells (2–10,000 cells/well), when cocultured on MS5
cell feeder layers in three- or six-cytokine conditions, re-
producibly generated CD191 B, CD561 NK, and CD151/
MPO1 Gr/M cells in 2–3 wk (Table I). In the presence of
six cytokines, up to 70% of cells recovered after 2 wk of cul-
ture were still CD341 (not shown). Table I and Fig. 2 A–C
also show that CD341CD192 cells collected from the mar-
row of NOD-SCID mice (n 5 4) and cultured for 3 wk in
the presence of six cytokines generated 3.1 6 0.7% CD191
B cells, 9.5 6 4.1% CD561 NK cells, and 22 6 13% CD151
Gr/M cells (mean 6 SEM of nucleated cells). Interestingly,
all three cell types also exhibited almost nonoverlapping for-
ward scatter versus side scatter profiles. Similar differentia-
tion profiles and lineage yields were observed in three ex-
periments initiated with CD341CD192CD382 cells (1 6
0.4, 44 6 3, and 28 6 5% B, NK, and Gr/M cells, respec-
tively) and CD341CD192Thy11 cells (6.4 6 6, 47 6 9,
and 20 6 5% B, NK, and Gr/M cells, respectively) (Table I).
Cells coexpressing CD1a and HLA-DR, most likely of
dendritic origin, were detected in a few experiments in
which these markers were analyzed (data not shown). As pre-
viously described, cultured CD191 cells coexpressed CD38
and CD10 but lacked CD20, CD22, and sIgM, whereas NK
cells were mature and functional, as shown by their sponta-
neous cytotoxic activity against K562 and Daudi cells (refer-
ence 31; data not shown).
CD341CD192 Human Cells Isolated from NOD-SCID
Recipients Express T Lymphoid Potential in FTOC. The cul-
ture conditions described above were not permissive to T cell
Figure 1. Selection of human cell populations. Human CD341 cells purified from fresh CB (A and B) and NOD-SCID marrow (C, D, and E) were
first depleted of CD191 cells (A and C). CD341CD192 cells were further enriched for Thy11 cells (B and D) or CD382 cells (E). Gates selected for cell
sorting are indicated in B (CD341CD192Thy11), D (CD341 CD192Thy11), and E (CD341CD192CD382). Limits of the quadrants were determined by
analyzing cells labeled with isotype-control Ig.1604 Transplantable and Totipotent Lymphomyeloid Cells in Human Cord Blood
differentiation, which requires the presence of thymic stro-
mal elements. We have recently reported the successful use
of NOD-SCID embryonic thymus to identify T cell po-
tential of CB and adult marrow CD341, CD341CD381,
and CD341CD382 cells (24). Here, we applied this strat-
egy to demonstrate that human CD341CD192 cells selected
from the bone marrow of NOD-SCID mice generated
CD4bright and double positive (DP) CD41CD81 T cells in
NOD-SCID FTOC. As illustrated in Fig. 2 B–G, in 5/5 ex-
periments, human CD41 cells (which represented 69 6 13%
of nucleated cells collected from thymi) were produced, and
82  6 5% of those were CD4bright, 46 6 12% were DP
Figure 2. Assessment of the Gr/M and lymphoid potentials of human CD341CD192 cells from the marrow of NOD-SCID mice transplanted with
CB CD341 cells. 10,000 human CD341CD192 cells obtained from the marrow of NOD-SCID mice 4 mo after transplantation with 105 human CB
CD341 cells were cultured on MS5 cells with six cytokines (A–C) or in chimeric FTOC (D–G). Cells cultured on MS5 were stained with CD15-FITC,
CD19-PE, and CD56-PE-Cy5, and cells grown in FTOC were stained with CD4-PE and CD8-FITC. In F and G, cells were analyzed after three-color
labeling (CD3-FITC, TCR-a/b-PE, and CD4-PE-Cy5). Labeled cells were analyzed on a FACScan™ (CellQuest software) in the morphological gates
indicated in A and D, which included all viable nucleated cells. Positivity set by the quadrant limits was defined using isotype-control Ig. These results are
from one representative experiment in which FTOCs and stromal cultures were initiated with human cells purified from NOD-SCID mice.
Table I. Phenotype of Human Cells Grown from CD341CD192, CD341CD192Thy11, and CD341CD192CD382 Cells from Fresh 
CB and NOD-SCID Mice
Cell fraction No. of experiments Cytokines* Time in culture
Proportion of cells in the gate‡
(mean 6 SEM)
CD191 CD561 CD151
wk
Fresh CB
CD341CD192 2 6 2 0.3; 0.2 1.4; 5 24; 36
1 6 3 0.4 45 34
CD341CD192Thy11 2 3 2-3 5.7 6 1.1 10 6 6 24 6 6
NOD-SCID mice
CD341CD192 4 3 2 19 6 6.4 44 6 15 6 6 1
4 6 3 3.1 6 0.7 9.5 6 4.1 22 6 13
CD341CD192Thy11 3 6 4-6 6.4 6 6 47 6 9 20 6 5
CD341CD192CD382 3 6 4-6 1 6 0.4 44 6 3 28 6 5
*Cytokines, 3 5 IL-2, IL-15, and SCF; 6 5 IL-2, IL-15, SCF, PEG-rhu-MGDF, Flt3-L, and IL-7.
‡The proportions of cells are calculated in the morphological gate indicated on Fig. 2 A. SEM was calculated if .2 experiments were available. Oth-
erwise, results for individual experiments are indicated.1605 Robin et al.
CD41CD81, 31 6 5% were CD41TCR-a/b1 (n 5 3), and
32 6 7% were CD41CD31 (n 5 3). As described for fresh
CB cells, very few CD42CD81 cells were produced (22).
Taken together, these experiments demonstrated that
CD341CD192 human cells detected in NOD-SCID re-
cipients 4 mo after intravenous injection of CD341 CB
cells had retained the ability to differentiate into B, NK,
and Gr/M lineages as well as T cells in vitro, even though
T and NK terminal maturation did not occur in vivo.
Single CD341CD192Thy11 and CD341CD192CD382
Cells from Fresh CB and Transplanted NOD-SCID Mice Are
Capable of Generating T, B, NK, and Gr/M Cells. Before in-
vestigating the full lymphomyeloid differentiative potential
of single cells, we first determined the frequency of single
cells that produce high numbers of B, NK, and Gr/M cells
when cocultured on MS5 cells with six cytokines.
In two experiments, 180 single CD341CD192 cells from
fresh CB were cultured in the presence of six cytokines and
MS5 cell feeder layers. Cells from 55 wells were pheno-
typed and found to contain multiple combinations of B,
NK, and Gr/M cells (Table II). Nine clones (16%) con-
tained cells from all three lineages, and 54% of the clones
yielded cells of only one lineage. When CD341CD192
Thy11 cells were used, the frequency of the three-lineage
clones increased to 28% (28 clones analyzed) and the fre-
quency of one-lineage clones decreased (21%), in agree-
ment with the preferential expression of Thy1 by imma-
ture progenitors. Lineages were similarly distributed in
clones grown from single CD341CD192Thy11 or CD382
cells isolated from the marrow of transplanted NOD-SCID
mice. Analysis, for instance, of cells from 240 wells, each
seeded with a single CD341CD192Thy11 (120 wells) or
CD341CD192CD382 (120 wells) cell, indicated that .50%
of the clones contained cells of two lineages and 15–33% cells
of three lineages but only 13–23% cells of one lineage (Table
II). In contrast and as noted above, 69% of the more mature
CD341CD192 cells generated cells of only one lineage.
Importantly, individual clones grown as described above
in six cytokines on stromal feeders contained high numbers
of nucleated cells (from 10,000 to 400,000 total cells per
well at week 2–3), which made it possible to remove part
of the clone to separately assay T cell differentiation in
FTOC. Thus, in a second set of experiments, multiple
wells were seeded with CD341CD192Thy11 from fresh
CB (420 wells) and with CD341CD192Thy11 and CD341
CD192CD382 cells from the marrow of transplanted NOD-
SCID mice (each population, 240 wells). After 2–3 wk,
clones that had proliferated (150, 76, and 92, respectively)
were divided to initiate NK-B-Gr/M and FTOC assays
(Table III).
The most remarkable result was that 10/150 clones
grown from fresh CD341CD192Thy11 CB cells and 14/
68 clones grown from human CD341CD192Thy11 (or
CD382) cells from NOD-SCID chimeras generated not
only B, NK, and Gr/M cells but also T cells (CD4bright cells
usually associated with DP CD41CD81 cells) in FTOC as-
says (Table III). As illustrated in Fig. 3, the proportions of
lymphoid (CD191, CD561) and Gr/M (CD151) cells var-
ied between clones. However, the distribution of clones
containing one, two, three, or four lineages in experiments
initiated with either fresh CB cells or cells from NOD-
SCID mice was almost identical (Table III). Interestingly,
the distribution of lineages was not strictly identical in
clones grown from CD341CD192Thy11 and CD341
CD192CD382 NOD-SCID–derived human cells. The bio-
logical significance of this observation is unclear, and this
result must be confirmed in experiments initiated with
fresh CB cells of both phenotypes. In addition to totipotent
clones, multiple combinations of lineages were detected:
30% of the clones (45/150 wells seeded with CD341
CD192Thy11 fresh CB cells and 27/92 wells seeded with
CD341CD192CD382 cells from transplanted NOD-SCID
mice) generated combinations of three lineages. Among
these three-lineage clones, 30% included T cells, and 4%
Table II. Lymphoid (B, NK) and Granulocytic Potentials of Single CD341 Cells from Fresh CB and NOD-SCID Mice
CD341
fractions No. of wells*
No. of wells with cells of the indicated lineage
one lineage‡ two lineages three lineages
NK B M Total % NK/B NK/M B/M Total % NK/B/M Total %
Fresh CB
CD192 180/55 8 2 20 54 13 2 1 29 9 16
CD192Thy11 120/28 2 1 3 21 13 0 1 50 8 28
NOD-SCID mice
CD192 600/90 40 1 21 69 14 5 2 23 8 9
CD192Thy11 120/30 0 0 4 13 14 2 0 53 10 33
CD192CD382 120/34 3 1 4 23 19 1 1 62 5 15
M, CD151 cells.
*Numbers refer to the ratio of the total no. of wells initiated/no. of wells analyzed.
‡Proportions were calculated as the ratio of clones containing one, two, or three lineages per total no. of clones analyzed.1606 Transplantable and Totipotent Lymphomyeloid Cells in Human Cord Blood
(17, 19, 35), in contrast to those from human stromal cells,
support the differentiation of CD341 cells into pro-B cells;
although spontaneous terminal B cell maturation remains
compromised, probably because T helper function is lack-
ing, it can be induced (36). However, despite recent sug-
gestions that extra-thymic differentiation may occur in the
marrow environment (37) or in the gut and the unique
finding of CD31 human cells in the marrow of bgnuXid mice
engrafted with CD341 marrow cells (7), human T cells
never developed in vitro in MS5 cocultures. The presence
of an intact thymic structure remains essential, although re-
cent results indicate that thymic stromal feeders can replace
the intact thymus (27, 38). The observation that cultures
of embryonic thymic lobes, initially used to follow mouse
T cell development, could be successfully applied to the
study of human T cell differentiation represents an improve-
ment over the use of human embryonic thymus. Thus, we
(24) and others (22, 23) recently described that FTOC initi-
ated with thymic lobes from immunodeficient mice efficiently
supported the first steps of human T cell differentiation up to
the DP CD41CD81 stage and are sensitive enough to detect
the production of CD41CD81 T cells from as few as 100
CD341 CB cells (24).
To prove cell totipotency, it was essential to work at the
clonal level, which imposed the need to initiate FTOC and
cocultures on MS5 feeders with cells issued from the same
clone. This required induction of the proliferation of input
combined B, NK, and T cells but no CD151 cells and were
most likely derived from lymphoid-restricted progenitors
(Fig. 4 A). None of the clones contained B cells alone and
,2% exclusively T cells (Table III). Both T (52/54) and B
(151/154) cells were almost always combined with NK
cells. This was the predominant phenotype in our culture
conditions: 128/150 clones from fresh CB and 145/168
clones from marrow of transplanted NOD-SCID mice
contained human NK cells.
Discussion
In this study we provide, for the first time in humans,
direct evidence that a significant proportion of CD341
CD192Thy11 (and/or CD382) fresh CB cells are totipo-
tent and that similar totipotent cells can be isolated from the
marrow of NOD-SCID mice transplanted several months
earlier with fresh human CD341 CB cells. The ability of a
single cell to generate T, B, and NK lymphocytes and Gr/M
cells defines totipotency and was demonstrated in vitro by
combining FTOCs and cocultures on competent murine
stromal cell feeder layers.
A prerequisite for the success of these experiments was to
first overcome previous limitations in the assay system for B
and T lymphoid potential of human cells in vitro, and a de-
cisive step was to use the murine stromal cell line MS5
(34). Feeder layers from MS5 and other cell stromal lines
Table III. Analysis of the Progeny of Single CD341CD192 or CD341CD192Thy11 or CD341CD192CD382 Subpopulations from 
Fresh CB and NOD-SCID Mice
CD341CD192
fractions No. of wells*
No. of wells with cells of the indicated phenotype‡
one lineage two lineages
NK M T Total % NK/B NK/M B/M M/T NK/T Total %
Fresh CB
Thy11 420/150 30 16 3 33 25 15 1 1 4 31
NOD-SCID mice
Thy11 240/76 29 15 0 58 11 11 1 0 0 30
CD382 240/92 14 6 1 23 20 8 0 0 3 34
CD341CD192
fractions No. of wells*
three lineages four lineages
NK/B/M M/B/T NK/M/T NK/B/T Total % NK/B/T/M Total %
Fresh CB
Thy11 420/150 31 1 4 9 30 10 7
NOD-SCID mice
Thy11 240/76 8 0 0 0 10 1 1.3
CD382 240/92 19 0 4 4 29 13 14
M, CD151 cells.
*Numbers refer to the total no. of wells initiated/no. of wells analyzed.
‡Proportions were calculated as the ratio of clones containing one, two, three, or four lineages per total no. of clones analyzed.1607 Robin et al.
single cells to allow subdivision of the clone without loss of
potentials. This was accomplished by adding early-acting
proliferative cytokines, including IL-7, to avoid the loss of
early T cell progenitors (33) and by plating the cells directly
on MS5 cells, because we have shown that these stromal
cells are important to retain the primitive potential of ac-
tively proliferating adult CD341CD382 marrow long-term
culture–initiating cells (39).
Our results showed that 6.7% of CD341CD192Thy11
CB cells were totipotent, which leads to an estimate of one
totipotent progenitor per 200 CD341 CB cells. This num-
ber is surprisingly high and may even be underestimated, as
we selected only actively proliferating clones and also be-
cause the hanging drop procedure that we used may limit
the homing of T cell progenitors into thymic lobes. Al-
though it is hazardous to draw any firm conclusion about
stem cell hierarchy based on the distribution and combina-
tion of lineages observed in single clones grown in vitro,
both were very similar to those reported from the analysis
of lymphomyeloid clones grown in vitro from murine fetal
liver (26) or embryonic splanchnopleura (40) and in vivo
from recipients of genetically marked donor cells (1). Par-
ticularly interesting was the observation in our study that
some clones, derived from fresh CB cells and the marrow
of transplanted NOD-SCID mice, produced T, B, and NK
but no Gr/M cells. Although we cannot exclude that other
conditions could have unmasked additional myeloid poten-
tials, erythroid or megakaryocytic, the total lack of CD151
cells makes this hypothesis very unlikely. The parental pro-
genitors most probably represented the human counterpart
of the murine lymphoid-restricted progenitors identified
among IL-7Ra1c-kit1Lin2Sca1 adult mouse marrow cells
(28). As reported in the mouse (26), we also failed to detect
bipotent T/B progenitors, an observation that contrasted
with the high frequency, in our study, of clones with both
NK and B cells. It is important to stress that NK cells were
the most frequent cell type in our cultures and that their
outgrowth might have interfered (in a positive or negative
way) with the development/survival of other lineages. In-
deed, there were very few if any clones containing only B
or T cells. A possible explanation for the lack of B cell
clones was the lack of signals released by T cells, which was
not compensated for by the action of MS5 cells.
A second major observation was that human totipotent
cells were detected in the marrow of NOD-SCID recipi-
ents several months after transplantation of CD341 CB
cells. Tracing individual stem cell fate and function in vivo
is complicated in the NOD-SCID chimeras, as opposed to
the syngenic murine situation, as terminal T and NK cell
differentiation, in contrast to B cell differentiation, does not
Figure 3. Production of T, B, NK, and
Gr/M cells by single CD341CD192CD382
cells from the marrow of NOD-SCID mice
transplanted with CB CD341 cells. Analysis
of the progeny of four individual clones is
shown (A–D). Single CD341CD192CD382
cells were cultured on MS5 with a cocktail
of six cytokines during 2 wk and the prog-
eny separated to initiate secondary MS5
cocultures and FTOC. Cells were cultured
for another 2 wk with MS5 and cytokines
and an additional 4 wk in FTOC, after
which time they were labeled with lineage-
specific antibodies as described in the Fig. 2
legend. Analysis was performed in the gates
defined in Fig. 2, A and D.1608 Transplantable and Totipotent Lymphomyeloid Cells in Human Cord Blood
take place in vivo. However, human CD341 cells isolated
from NOD-SCID chimeras reproducibly produced CD41
CD81 T cells and NK cells in vitro, indicating that human
cells have not lost their intrinsic T and NK potential after
their engraftment in the NOD-SCID environment. A
more likely hypothesis is that regulatory steps involved in
the development of T and NK pathways do not take place
in this xenogenic model. For T cells, the defect most likely
involves molecules regulating cell trafficking, whereas the
maturation of human NK cells was blocked because human
cells do not respond to murine IL-2 and IL-15.
A close frequency of totipotent clones (7%) was found in
experiments initiated with fresh CD341CD192 Thy11 CB
cells and CD341CD192CD382 cells from transplanted
NOD-SCID mice (14%). Calculations yielded an absolute
number of z50 totipotent cells in four long bones of a
NOD-SCID 4-mo posttransplant. Considering that 500
totipotent cells were present among the 105 CD341 cells
injected, this suggests loss rather than amplification of toti-
potent cells. However, totipotent clones may in fact ac-
tively proliferate in vivo. A strong argument in favor of this
hypothesis is that, in our experience as well as in others’ (8),
,1% of the injected CD341 human cells are detected in the
marrow of NOD-SCID mice 48 h after their injection
(range 0.1 to 4% in six experiments; our unpublished data).
Therefore, it is conceivable that ,10 totipotent cells eventu-
ally colonize the marrow of NOD-SCID mice and contrib-
ute to the reconstitution of all compartments, a hypothesis
that is in agreement with murine studies (1, 4, 41, 42). Defi-
nite determination of the number of human clones contrib-
uting to the reconstitution of hematopoiesis in NOD-SCID
mice will await results from transplantation experiments us-
ing genetically marked human cells. These studies will be fa-
cilitated by the availability of conditions that allow the ex-
pression of the full differentiative potentials of individual
clones, as demonstrated in this study, but also by improved
procedures that will allow efficient transduction of NOD-
SCID-CRU competitive repopulating unit (43, 44).
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